

Journal of Visualized Experiments

In Vitro Bioluminescence Assay to Characterize Circadian Rhythm in Mammary Epithelial Cells --Manuscript Draft--

Manuscript Number:	JoVE55832R2
Full Title:	In Vitro Bioluminescence Assay to Characterize Circadian Rhythm in Mammary Epithelial Cells
Article Type:	Invited Methods Article - JoVE Produced Video
Keywords:	circadian rhythm, PERIOD 2, promoter activity, In vitro real-time bioluminescence assay, luciferase expression vector, destabilized firefly luciferase, plasmid transfection
Manuscript Classifications:	95.51: Life Sciences (General)
Corresponding Author:	M Fang Rutgers School of Public Health Piscataway, NJ UNITED STATES
Corresponding Author Secondary Information:	
Corresponding Author E-Mail:	fang@eohsi.rutgers.edu
Corresponding Author's Institution:	Rutgers School of Public Health
Corresponding Author's Secondary Institution:	
First Author:	M Fang
First Author Secondary Information:	
Other Authors:	Hwan-G. Kang
	Youngil Park
	Brian Estrella
	Helmut Zarbl
Order of Authors Secondary Information:	
Abstract:	<p>The circadian rhythm is a fundamental physiological process present in all organisms that regulates biological processes ranging from gene expression to sleep behavior. In vertebrates, circadian rhythm is controlled by a molecular oscillator that functions in both suprachiasmatic nucleus (central pacemaker) and individual cells comprising most peripheral tissues. More importantly, disruption of circadian rhythm by exposure to light-at-night, environmental stressors and/or toxicants is associated with increased risk of chronic diseases and aging. The ability to identify agents that can disrupt central and/or peripheral biological clocks, and agents that can prevent or mitigate the effects of circadian disruption, has significant implications for prevention of chronic diseases. Although rodent models can be used to identify exposures and agents that induce or prevent/mitigate circadian disruption, these experiments require large numbers of animals. In vivo studies also require significant resources and infrastructure, and require researchers to work all night. Thus, there is an urgent need for a cell-type appropriate in vitro system to screen for environmental circadian disruptors and enhancers in cell types from different organs and disease states. We constructed a vector that drives transcription of the destabilized luciferase in eukaryotic cells under the control of the human PERIOD 2 gene promoter. This circadian reporter construct was stably transfected into human mammary epithelial cells, and circadian responsive reporter cells were selected to develop the in vitro bioluminescence assay. Here, we present detailed protocols for each of the steps used to establish and validate the assay. We further provide details for proof of concept experiments demonstrating the ability of our in vitro assay to recapitulate the in vivo effects of various chemicals on the cellular biological clock. The results indicate that the assay can be adapted to a variety</p>

	of cell types to screen for both environmental disruptors and chemopreventive enhancers of circadian clocks.
Author Comments:	I could not select classification online. The website somehow does not work for that now. Any suggestion?
Additional Information:	
Question	Response
If this article needs to be "in-press" by a certain date, please indicate the date below and explain in your cover letter.	



NIEHS Center for Environmental Exposures and Disease
Environmental & Occupational Health Sciences Institute
Department of Environmental and Occupational Health
School of Public Health
Rutgers, The State University of New Jersey
170 Frelinghuysen Road, Room 412
Piscataway, NJ 08854

Mingzhu Fang, MD, PhD, DABT
Assistant Professor
Tel. 848-445-3720
Fax. 732-445-4161
fang@eoehsi.rutgers.edu

May 5, 2017

Indrani Mukherjee Ph.D.
Science Editor
JoVE
One Alewife Center, Suite 200, Cambridge, MA 02140

Dear Dr. Indrani Mukherjee,

Please find the second revised version of our manuscript titled "In Vitro Bioluminescence Assay to Characterize Circadian Rhythm in Mammary Epithelial Cells" by Fang *et al.*, according to the editor's comments.

As requested by the editor, we uploaded revised manuscript, figure 2-4, and response to comments. We hope the revised manuscript now is qualified for publication.

As mentioned in the previous cover letter, in the representative result part, we appropriately cited one figure (Fig. 3) that has been published in *Oncotarget* last year an open access journal providing creative commons license that allows us to re-use our figure for publication in JoVE. This license is attached here (Attachment 1).


All the coauthors have agreed on the content of this manuscript and the results have not been submitted for publication in any other journals. Six suggested reviewers' information is also attached here (Attachment 2).

We thank you in advance for your consideration and look forward to hearing from you regarding what we believe is an important study.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Mingzhu Fang".


Mingzhu Fang

 **creative commons**

Attribution 3.0 Unported (CC BY 3.0)

This is a human-readable summary of (and not a substitute for) the [license](#).

[Disclaimer](#)



You are free to:


Share — copy and redistribute the material in any medium or format

Adapt — remix, transform, and build upon the material

for any purpose, even commercially.

The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:



Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Appendix 2

Suggested 6 Reviewers:

Zui Pan, pan.361@osu.edu, College of Medicine, Ohio State University

Shelley Tischkau, stischkau@siumed.edu, Southern Illinois University School of Medicine

Zheng Chen, zheng.chen.1@uth.tmc.edu, UTHealth Medical School

Andrew C. Liu acliu@memphis.edu,

Ming Gong ming.gong@uky.edu University of Kentucky

Nihal Ahmad, nahmad@wisc.edu, UW School of Medicine & Public Health

TITLE:

In Vitro Bioluminescence Assay to Characterize Circadian Rhythm in Mammary Epithelial Cells

AUTHORS & AFFILIATIONS:

Mingzhu Fang¹, Hwan-Goo Kang², Youngil Park², Brian Estrella¹, Helmut Zarbl¹

¹Department of Environmental and Occupational Health, School of Public Health, NIEHS Center for Environmental Exposures and Disease, Environmental and Occupational Health Sciences Institute, Rutgers, The State University of New Jersey, Piscataway, NJ08854, USA

²Veterinary Drugs & Biologics Division, Animal and Plant Quarantine Agency, Gimcheon-si, Gyeongsangbuk-do, Republic of Korea

E-MAIL ADDRESSES:

Mingzhu Fang (fang@eohsi.rutgers.edu)

Hwan-G. Kang (Kanghg67@korea.kr)

Youngil Park (Pyi@korea.kr)

Brian Estrella (Brian.Estrella@rutgers.edu)

Helmut Zarbl (zarbl@eohsi.rutgers.edu)

CORRESPONDING AUTHOR:

Mingzhu Fang, Ph.D.

Tel: 1-848-445-3720

KEYWORDS:

Circadian rhythm, *PERIOD 2*, promoter activity, *in vitro* real-time bioluminescence assay, luciferase expression vector, destabilized firefly luciferase, plasmid transfection.

SHORT ABSTRACT:

An *in vitro* bioluminescence assay to determine cellular circadian rhythm in mammary epithelial cells is presented. This method utilizes mammalian cell reporter plasmids expressing destabilized luciferase under the control of the *PERIOD 2* gene promoter. It can be adapted to other cell types to evaluate organ-specific effects on circadian rhythm.

LONG ABSTRACT:

The circadian rhythm is a fundamental physiological process present in all organisms that regulates biological processes ranging from gene expression to sleep behavior. In vertebrates, circadian rhythm is controlled by a molecular oscillator that functions in both the suprachiasmatic nucleus (SCN; central pacemaker) and individual cells comprising most peripheral tissues. More importantly, disruption of circadian rhythm by exposure to light-at-night, environmental stressors and/or toxicants is associated with increased risk of chronic diseases and aging. The ability to identify agents that can disrupt central and/or peripheral biological clocks, and agents that can prevent or mitigate the effects of circadian disruption, has significant implications for prevention of chronic diseases. Although rodent models can be used to identify exposures and agents that induce or prevent/mitigate circadian disruption, these

experiments require large numbers of animals. *In vivo* studies also require significant resources and infrastructure, and require researchers to work all night. Thus, there is an urgent need for a cell-type appropriate *in vitro* system to screen for environmental circadian disruptors and enhancers in cell types from different organs and disease states. We constructed a vector that drives transcription of the destabilized luciferase in eukaryotic cells under the control of the human *PERIOD 2* gene promoter. This circadian reporter construct was stably transfected into human mammary epithelial cells, and circadian responsive reporter cells were selected to develop the *in vitro* bioluminescence assay. Here, we present a detailed protocol to establish and validate the assay. We further provide details for proof of concept experiments demonstrating the ability of our *in vitro* assay to recapitulate the *in vivo* effects of various chemicals on the cellular biological clock. The results indicate that the assay can be adapted to a variety of cell types to screen for both environmental disruptors and chemopreventive enhancers of circadian clocks.

INTRODUCTION:

The circadian clock regulates a wide range of biological processes from diurnal expression of genes to sleep behavior in a predictable rhythm with a periodicity of approximately 24 h. Epidemiological studies strongly suggest that chronic disruption of circadian rhythm increases the risk of breast and prostate cancer in shift workers, including nurses and flight crews¹⁻³. These findings are corroborated by rodent studies, demonstrating that exposure to constant light, light-at-night, or light cycles that mimic jet-lag increase tumor incidence and accelerates tumor growth^{4,5}. Based on data from both human and rodent studies, the International Agency for Research on Cancer classified shift-work as a probable human carcinogen (Type 2A) in 2010⁶.

Previously, we demonstrated that a single carcinogenic dose of the mammary tumor specific carcinogen, *N*-nitroso-*N*-methylurea (NMU), disrupted the circadian expression of major circadian genes (CGs) (*e.g.*, *Period 2*, *Per2*) and several circadian-controlled genes (CCGs), including key DNA damage responsive and repair (DDRR) genes in the target mammary gland (but not in the liver). Moreover, resetting the circadian expression of both *Per2* and DDRR genes towards the normal by a chemopreventive regimen of dietary *L*-methyl-selenocysteine (MSC) reduced the incidence of tumor by 63%. These findings were the first to show a mechanistic link between circadian rhythm, chemical carcinogenesis and chemoprevention^{7,8}. Exposures to other environmental toxicants shown to disrupt circadian gene expression *in vivo* are also associated with increased risk of environmental diseases^{9,10}. Understanding the mechanisms that link circadian disruption by environmental toxicants and pathogenesis may lead to mechanistically-based approaches to disease prevention. However, studies aimed at defining the interactions between the exposures and circadian rhythm are usually performed *in vivo*. A typical *in vivo* experiment investigating the impact on circadian rhythm requires large numbers of animals, as tissues from at least three control and three exposed animals must be collected every 3–4 h over a 24 or 48 h period. Development of a validated *in vitro* system that recapitulates *in vivo* observations and mechanisms would therefore not only reduce the number of animals required, but also dramatically reduce experimental costs and the requirement that researchers work continuously over a 24–48 h period. Moreover, a validated

in vitro system could be used for high throughput screening of compounds and/or genetic alteration that affect circadian rhythm, or its response to environmental stressors or toxicants. Therefore, the strategical combination of *in vitro* and *in vivo* models and experiments are needed to obtain different insights with different focus.

In mammals, circadian oscillators exist not only in specialized neurons of the SCN, but also in most peripheral cell types. These molecular clocks are similar to those in established fibroblast cell lines and in primary fibroblasts from embryos or adult animals; however, there is a need for tissue type-specific cellular models¹¹. Consequently, traditional studies of locomotor activity *in vivo*, SCN explants *ex vivo*, and cell-based *in vitro* assays in immortalized fibroblast cells are widely used to study cell-autonomous circadian defects. However, there is no evidence indicating that an *in vitro* fibroblast cell-based assay can recapitulate circadian mechanisms and responses present in cells of other peripheral organs *in vivo*. Different cell types can have distinct patterns of gene expression, xenobiotic metabolism, and DDRR, and the links between toxicity and circadian gene expression may be cell-type specific and/or modulated by different physiological parameters. In addition, circadian oscillators in fibroblast-based systems have not been fully assessed for responses to environmental toxicants, stressors and preventive agents that link exposures to mechanisms of disease development and prevention. Thus, there is a need for facile, validated cell-type specific, *in vitro* bioluminescence assays to study organ specific environmental circadian disruptors. Although a variety of cellular clock models (*e.g.*, in liver, keratinocytes, and fat cells, as well as an osteosarcoma cell line) have been developed in recent years¹²⁻¹⁵, the assay described here is the first cellular clock model in breast epithelial cells, and the first demonstration to recapitulate *in vivo* responses to environmental stressors, toxicants, drugs, and chemopreventive agents.

Renilla luciferase (*rLuc*) and firefly luciferase are 30–61 kDa monomeric proteins that do not require posttranslational processing for enzymatic activity and can function as a genetic reporter immediately upon translation. Once the substrate associates with the luciferase enzyme, the biochemical reaction catalyzed generates a flash of light. Thus, luciferase constructs are widely used as a gene expression reporter system *in vitro* and *in vivo*. However, in circadian rhythm studies, the utility of the luciferase reporter is limited by the relatively long half-life of the luciferase protein ($T_{1/2} = 3.68$ h) relative to the period (especially to the short period) for changes in circadian gene expression; however, numerous studies over the years have successfully used the luciferase gene in the pGL3 vector, indicating that the rapidly degradable luciferase may not be necessary for reporting circadian rhythms, especially for the rhythms with a longer period, such as 24 h. Therefore, a reporter plasmid using destabilized luciferase vector, pGL[*Luc2P*/Neo], that contains hPEST (a protein destabilization sequence) has been developed, allowing us to use it as a circadian reporter vector for our current *in vitro* bioluminescence assay. The protein encoded by *Luc2P* has a much shorter half-life ($T_{1/2} = 0.84$ h) and hence, responds more quickly and with a greater magnitude to changes in transcriptional activity than wild-type, indicating that it can be used to monitor the rhythmic expression of luciferase regulated by the *PER2* promoter accurately in real-time¹⁶.

PROTOCOL:

1. Construction of *PER2* Promoter Driven Destabilized Luciferase Reporter Vector

1.1. Purchase a customized pLS[*hPER2P/rLuc/Puro*] vector that contains cDNA encoding *rLuc* and human *PER2* promoter fragment (hPER2P, 941 bp) at the site between *Sac* I and *Hind* III in the multiple cloning region¹⁷.

1.2. Cut the human *PER2* promoter fragment (hPER2P, 941 bp) out from the vector.

1.2.1. Add 2.5 µL restriction enzyme buffer, 10 µL (180 ng) pLS[*hPER2P/rLuc/Puro*] vector, and 1 µL each of the restriction enzymes, *Sac* I (10 unit/µL) and *Hind* III (10 unit/µL), into a DNA/RNA/nucleotide-free microcentrifuge tube. Add ultrapure water (10.5 µL) up to 25 µL and mix gently by pipetting.

1.2.2. Incubate at 37 °C for 90 min in a heating block.

1.2.3. Run the whole volume (25 µL) of the restriction enzyme reaction on 0.7% agarose gel containing 0.0001% ethidium bromide (EtBr) to separate the hPER2P from the vector.

Note: EtBr, 3,8-diamino-1-ethyl-6-phenylphenanthridinium bromide (CAS registration number: 1239-45-8), is an odorless red liquid. It is an intercalating agent that is commonly used as a fluorescent tag (nucleic acid stain) in agarose gel electrophoresis and visible as an orange color under UV light. Possible risks of irreversible mutagenic effects have occurred in experimental animals, although none of the regulatory agencies categorized it as a carcinogen¹⁸. Therefore, we collected used agarose gel and electrophoresis buffer containing EtBr as chemical hazard waste, and requested Rutgers Environmental Health & Safety (REHS) to pick up and dispose safely.

1.2.4. Cut a piece of agarose gel containing a EtBr fluorescence band at 941 bp, and purify the hPER2P fragments from the gel with a DNA gel extraction kit, followed by quantification on a spectrophotometer by measuring absorption density (OD) at 260 nm wavelength.

1.3. Linearize 1.0 µL (1 µg) of the destabilized firefly luciferase expression vector, pGL[*Luc2P/Neo*] with the same method as described in steps 1.2.1–1.2.2. Extract the vector with a DNA clean-up kit followed by quantification as described above using a spectrophotometer.

1.4. Ligate the hPER2P into the linearized vector pGL[*Luc2P/Neo*].

Note: Per the manufacturer's instruction, the ideal molar ratio of insert and vector is 2:1. For 50 ng vector, the ideal amount of insert is calculated as 23.6 ng with a formula, [(50 ng vector x 1.0 kb insert)/4.242 kb vector] x (2/1) = 23.6 ng insert]. Based on the concentrations of hPER2P (7.26 ng/µL) and pGL[*Luc2P/Neo*] (50 ng/µL), the volumes of 50 ng pGL[*Luc2P/Neo*] and 23.6 ng hPER2P are calculated as 1 µL and 3.26 µL, respectively.

1.4.1. Add 2 μL T4 DNA ligase reaction buffer (10X) (50 mM Tris-HCl, 10 mM MgCl_2 , 1 mM ATP, and 10 mM DTT), 3.26 μL (23.6 ng) hPER2P, 1 μL (50 ng) pGL[*Luc2P/Neo*], and 13.74 μL water up to 20 μL , mix gently.

1.4.2. Add 1 μL T4 DNA ligase (400 unit/ μL), mix gently and incubate at 16 °C overnight in a thermocycler, and then chill the ligated vector on ice per the manufacturer's instruction.

1.5. Transform the ligated vector pGL[*hPer2P/Luc2P/Neo*] to chemically competent *E. coli* ¹⁹.

1.5.1. Set the water bath at 42 °C, warm up Super Optimal Broth with catabolite repression (S.O.C.) medium (2% Tryptone, 0.5% Yeast Extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl_2 , 10 mM MgSO_4 , and 20 mM glucose) at room temperature, warm up Luria-Bertani (LB) agar plate (containing 100 $\mu\text{g}/\text{mL}$ ampicillin, 80 $\mu\text{g}/\text{mL}$ X-gal, and 0.5 μM IPTG) in 37 °C incubator, and thaw on ice one vial of competent *E. coli* cells for each transformation.

1.5.2. Add 6 μL (21 ng) ligated vector or 1 μL (30 ng) empty vector (negative control) to one tube of chemically competent *E. coli* (50 μL) and then gently flip the tube to mix. Incubate on ice for 30 min.

1.5.3. Heat shock in a 42 °C water bath for 30 s without shaking and then return to ice.

1.6. Select an *E. coli* colony transformed with a ligated vector using blue/white screening.

1.6.1. Add 250 μL S.O.C. medium in the transformed *E. coli* tube and incubate it for 1 h at 37 °C with shaking at 200 rpm.

1.6.2. Spread 10–50 μL of transformed *E. coli* on the surface of the LB agar plate evenly. Put the plate upside down in 37 °C incubator overnight.

Note: An efficient cloning reaction should produce several hundred colonies. Plating two different volumes is recommended to ensure that at least one plate will have big, clear white or blue color, and well-spaced colonies. When the colonies are too small and the color is not distinguishable, using a microscope (10X or 50X) is helpful.

1.6.3. Pick 3–6 white colonies from the plates with sterilized tooth sticks, and release each colony into one culture tube containing 4 mL of LB culture medium with 50 $\mu\text{g}/\text{mL}$ ampicillin.

1.6.4. Incubate the tubes at 37 °C with shaking at 200 rpm overnight. Extract the DNA using 2 mL of the 4 mL cultured *E. coli* with a plasmid DNA extraction mini prep kit per the manufacturer's instruction.

1.7. Verify and analyze the insert (hPER2P, 941 bp)

1.7.1. Digest the plasmid DNA with restriction enzymes and run electrophoresis as described in steps 1.2.1–1.2.3 to confirm if there is an insert.

Note: Positive control (hPER2P purified at step 1.2.4) and negative control (*E. coli* transformed with an empty vector) were included.

1.7.2. Sequence the selected plasmid DNA using M13 forward and M13 reverse primers to confirm the orientation and sequence of insert in the plasmid¹⁹.

Note: Only one colony that had an insert with the correct size of hPER2P in electrophoresis and correct orientation and sequence in the sequencing result was selected.

1.7.3. Analyze the human *PER2* promoter fragment (hPER2P, 941 bp) sequence for the circadian regulatory elements, including E-box motif (Bmal1 binding site, CAT/CGTG), CCAATC, GC box, and transcription start site (CAGCGG)²⁰.

1.8. Amplify the selected *E. coli* by adding the leftover 2 mL cultured *E. coli* into 200 mL LB culture medium containing 50 µg/mL ampicillin and then incubating it overnight at 37 °C with shaking at 200 rpm.

1.9. Extract DNA with an endotoxin-free plasmid maxi prep kit per the manufacturer's instruction, and then quantify it by measuring OD at 260 nm wavelength with a spectrophotometer. Aliquot and store the plasmid DNA, pGL[hPer2P/Luc2P/Neo], at -80 °C freezer for future use.

2. Transient Transfection

2.1. Purchase and culture MCF10A cells

2.1.1. Purchase an immortalized, non-transformed normal human mammary epithelial cell line (MCF10A) from a commercial cell bank, where cells are cytogenetically tested and authenticated with short tandem repeat analysis before freezing. Thaw and maintain each vial of frozen cells in culture for a maximum of 8 weeks.

Note: Unlike other cells, these cells have contact inhibition once they get to ~ 70% confluence. It requires that subculture is conducted at ~ 70%.

2.1.2. Culture the cells with mammary epithelial cell growth medium (MEGM), containing mammary epithelial basal medium (MEBM), growth supplements, and cholera toxin in a cell culture incubator at 37 °C, 95% humidity, and 5% CO₂.

Note: Purchase ready-to-use growth factors provided in SingleQuot (SQ) and obtain cholera toxin separately. Final concentrations of growth supplements are 0.4% bovine pituitary extract,

0.1% insulin, 0.1% hydrocortisone, 0.1% human epidermal growth factors, 100 ng/mL cholera toxin, and 0.05% gentamycin sulfate and 0.05% amphotericin B.

2.1.3. Dissociate the cells in 10-cm culture dish by incubation with 10 mL trypsin/EDTA for ~ 20 min and then neutralize the trypsin by adding 10 mL trypsin neutralizing solution. Collect all cells with HEPES buffered saline solution (HBSS).

2.1.4. Count the cells with a hemocytometer under an inverted microscope and calculate the concentration of the single cell suspension, and then seed a certain number of cells as needed. Swirl the plates thoroughly to obtain an even distribution of cells in each plate. Incubate cells in the cell culture incubator at 37 °C, 95% humidity and 5% CO₂.

Note: Purchase a subculture reagent pack containing trypsin/EDTA, trypsin neutralizing solution, and HBSS to use.

2.2. Transient transfection of cells with the circadian vector constructed.

2.2.1. Seed 2×10^5 MCF10A cells evenly in 35-mm culture dish with MEGM and grow to 20–30% confluence (next day).

2.2.2. Warm up the reduced serum media (*e.g.*, Opti-MEM) in 37 °C water bath and transfection reagent at room temperature for 30 min. Dilute the plasmid DNA constructed (pGL[hPer2P/Luc2P/Neo]) to 30 ng/μL with endo-toxin free Tris-EDTA (TE) buffer and keep at room temperature.

2.2.3. Prepare the plasmid transfection mixture in a 1.5 mL microcentrifuge tube by adding 63.6 μL warm reduced serum media first, then adding 33.4 μL (0.1 μg) plasmid DNA, and mix gently by pipetting, and then lastly adding 3 μL of transfection reagent directly into the center of the tube without touching the wall. After mixing gently by pipetting, keep at room temperature for 30 min.

2.2.4. Drop the entire plasmid mixture (100 μL) directly onto the center surface of the medium in the plate and then mix gently by shaking the dish. Culture the cells in a CO₂ incubator for additional 48–72 h.

Note: It is predicted that the highest transfection efficiency would be at 40–70% confluence of these cells due to their contact inhibition at ~ 70%. Therefore, transfection works best starting at ~ 20% and stop at ~ 70% confluence.

3. Establishment of the *In Vitro* Bioluminescence Assay in Transiently Transfected MCF10A Cells

3.1. Starve the cultured cells at ~70% confluence (after transfection for 48–72 h) in MEBM without growth factors for 24 h.

3.2. Treat the cells with synchronization agent (e.g., 50% horse serum (HS)) in MEBM for 1.5 h in a CO₂ incubator.

Note: For selection of an ideal synchronization agent, 10 μ M forskolin, 1 nM melatonin, 0.1 μ M dexamethasone, 50% HS, and 100% SQ were compared in terms of circadian amplitude and period in the circadian vector transfected cells. Empty vector transfected cells are treated with 100% SQ as a negative control.

3.3. Pre-prepare 20 mL recording medium (for 10 of the 30-mm culture dishes) by adding 5 mL of MEGM, 15 mL of MEBM, 150 μ L sodium bicarbonate, 200 μ L HEPES, and 40 μ L luciferin stock solution (50 mM) in a 50 mL sterilized centrifuge tube.

Note: The final concentrations of each components: 20% SQ and 20 ng/mL cholera toxin, 0.06% sodium bicarbonate, 1% penicillin/streptomycin, and 10 mM HEPES. Warm up pre-prepared recording medium and sterilized 1X PBS for 30 min in 37 °C water bath. Add 100 μ M luciferin immediately before use.

3.4. Wash the cells with warm 1X Dulbecco's Phosphate-Buffered Saline (D-PBS) for 3 times after the incubation with the synchronization agent, and then add 2 mL recording medium.

3.5. Seal the dish with a sterilized cover glass using silicon grease to prevent evaporation and then label it on the side.

3.6. Place the sealed dish in the seat inside the luminometer, and turn on the option for saving the file location in the folder (for the detail, see section 6).

4. Selection of Stably Transfected Cells

4.1. Optimize an ideal G418 concentration (800 μ g/mL) with a kill curve assay according to the manufacturer's instruction for selection of the stably transfected cells.

4.2. After transient transfection for 48 h or 72 h, subculture and seed the cells with MEGM in larger dishes at 5,000 cells/dish (100-mm). After 24 h culture in the cell culture incubator (37 °C, 95% humidity, and 5% CO₂), treat the cells with 800 μ g/mL of G418 by replacing the old medium with new medium containing 800 μ g/mL G418 every 3–4 days for 2 weeks.

4.3. Subculture the surviving stably transfected colonies for 1–3 passages with MEGM containing 500 μ g/mL G418 to maintain the stable expression of hPer2P/Luc2P, and freeze in liquid nitrogen for future use.

4.4. Treat 500 μ g/mL G418 after general subculture to re-select the stably transfected population of cells, if the bioluminescence intensity in the result of *in vitro* bioluminescence assay becomes progressively lower after use in many passages.

5. Treatment with Chemicals

5.1. At 48 h or 72 h post-transfection, starve the cells from growth factors in MEBM for 24 h.

5.2. After synchronization with 50% HS for 2 h, treat cells with 0.25 mM or 0.5 mM nitrosomethylurea (NMU), 20 nM EX527, or 1 μ M cambinol for 1 h in MEBM containing 20% SQ.

5.3. After washing with 1X D-PBS, add recording medium containing 12.5 μ M MSC alone, or in combination with 20 nM EX527 or 1 μ M cambinol, to the cells. Monitoring the bioluminescence with the luminometer.

5.4. Treat the stably transfected MCF10A/*PER2-dLuc* cells with NMU at 0.5, 1, or 2 mM, EX527 at 40 nM, or Cambinol at 2.0 μ M, for 1 h after synchronization with 50% HS, and then incubate the cells in recording medium containing 12.5 μ M of MSC or different doses (5, 10, or 20 μ M) of n-acetylcysteine (NAC). Place the plates in the luminometer, record and save the bioluminescence by luminometer for 4–8 days as described in section 3.6.

Note: NMU is a methylated nitrosourea compound with mutagenic, carcinogenic, and teratogenic properties. NMU is a direct-acting alkylating agent and has a short half-life ($T_{1/2} \sim 30$ min). It is stable at acidic condition (pH 4–5), but unstable at alkaline condition (pH 9–10) and at temperatures beyond 20 °C. Therefore, bleach at 10% can be used as an efficient deactivating agent for cleaning bench surfaces and lab wares potentially contaminated by NMU solution. Leftover stock solution is picked-up and safely disposed of by REHS. Based on the mode of action of chemicals, synchronized cells can be treated for shorter times before culturing in recording medium. Cells can also be treated in the recording medium for a longer time (several days).

6. Data Collection, Analysis, and Presentation

Note: Cell viability needs to be determined using standard methods (*e.g.*, MTT assay) after treatment of cells at the same concentrations for the same times indicated. All treatment concentrations used in the *in vitro* bioluminescence assay were lower than the 30% lethal concentration (LC30). All experiments were conducted in triplicate and representative results were presented.

6.1. After sealing the dish (step 3.5), load the dishes onto the seats in the luminometer, which is kept inside an incubator set at 37 °C without H₂O and CO₂, and connected to a computer.

6. 2. Click “save” and enter the names for the folder and file where the recorded luminescence signal from the corresponding dish will be saved.

Note: The system detects the luminescence signal in real-time from the cells in the dish at individual positions. The signals are transferred to the computer through 4-photon-counting photomultiplier tubes, and saved and displayed in the computer by the data collection software.

6.3. Analyze the signals after recording for 4–7 days, which could be followed by medium change and continuous recording for a second week if necessary.

Note: To obtain circadian parameters, including phase, period length, rhythm amplitude, and damping rate, we used the luminometer analysis software to analyze the bioluminescence data.

6.4. Detrend raw data with a running average, and analyze the best-fits to a sine wave to get period, phase, amplitude, and damping rate^{21,22}.

6.5. Due to the high transient bioluminescence upon treatment and medium change, exclude the first cycle of data from analysis.

6.6. For data presentation, plot raw data (bioluminescence, count/s) against time (h or day). When necessary, baseline-subtracted data can be plotted to compare amplitude and phase.

REPRESENTATIVE RESULTS:

Circadian bioluminescence reporter vector: human *PER2* promoter-driven expression of destabilized luciferase variant

The DNA sequence comprising a 941 bp fragment derived from the human *PER2* promoter used to construct the circadian reporter vector, pGL[*hPer2P/Luc2P/Neo*], was first analyzed for the presence of regulatory elements known to regulate circadian gene expression. Bioinformatics analysis showed that within this promoter fragment, there are three different Bmal1 binding sites (E-box) (CAT/CGTG), two circadian transcription enhancing sites (CCAATG), two GC boxes, and a transcription start site (**Figure 1**). Hence this reporter vector was anticipated to reflect circadian gene expression.

Optimization of synchronization agent

Several agents have been used to synchronize or affect the autonomous circadian rhythm of fibroblast cells for *in vitro* bioluminescence studies. To select an efficient and cost-effective cell-type specific synchronization agent in mammary epithelial cells, we compared 10 μ M forskolin, 1 nM melatonin, 0.1 μ M dexamethasone, 50% HS, and 100% SQ in mammary epithelial cells (MCF10A) transiently transfected with the circadian reporter vector. Cells synchronized with 50% HS showed the best circadian rhythm, with 3 peaks of circadian induced luminescence, compared to only one or two peaks in cells synchronized with other agents. In addition, the bioluminescence profiles of cells synchronized with 50% HS produced acceptable period, amplitude, and best-fit value during data analysis (**Figure 2**). Based on these findings, we selected this cost-effective method as the cell synchronization agent for all subsequent experiments.

Disruption and restoration of cellular circadian rhythm by chemical exposures

In this *in vitro* model, untreated, transiently transfected cells (control group) showed at least two complete cycles of luminescence signaling after synchronization (**Figure 3A**). Cells exposed to the direct acting mutagen, NMU, showed a dose-dependent disruption of circadian gene expression as reflected by the loss of luminescence peaks. While treatment with 0.25 mM NMU did not disrupt the cellular circadian rhythm, a dose of 0.5 mM NMU initially delayed and later abolished circadian rhythm, as indicated by the disappearance of the second peak of luminescence at ~ 72 h post-treatment. Inhibition of SIRT1 activity with 20 nM Ex257 or 1 μ M cambinol similarly disrupted circadian rhythm by dampening the subsequent circadian cycle (**Figure 3A(1)**). Importantly, the addition of MSC (12.5 μ M) to the culture medium restored towards normal first and second cycles of circadian gene expression in NMU-treated cells. MSC not only restored the rhythm disrupted by NMU, but also prevented the disruptive effects of SIRT1 inhibitors, Ex257 and cambinol (**Figure 3A(2)**).

In stably transfected cells, both NMU and SIRT1 inhibitors disrupted circadian rhythm, albeit at higher concentrations than that observed in transient transfectants (**Figure 3B(1)**). MSC (12.5 μ M) restored circadian rhythms in the cells pretreated with 1 mM NMU (**Figure 3B(2)**). More importantly, MSC also restored circadian rhythms in the cells treated with SIRT1 inhibitors, including EX257 (40 nM) (**Figure 3B(3)**) and cambinol (2 μ M) (**Figure 3B(4)**), respectively.

In comparison between **Figure 3A** and **Figure 3B**, the bioluminescence intensity was much higher but the rhythm was sustained for a shorter time in transiently transfected cells vs stably transfected cells (~ 10 times higher, 2 times shorter) in general, even after treatment of cells with NMU or MSC. In addition, the cellular circadian rhythm was 2-fold more sensitive to exposure to chemicals in transiently transfected cells compared to the stably transfected cells.

Quantitative dose-dependent change of cellular circadian rhythm by chemicals

Similarly, the disrupted cellular circadian rhythm of the stably transfected cells treated with 1 mM NMU was restored by the treatment of NAC in a dose-dependent manner (0–20 μ M) (**Figure 4A**) as observed in the changes of circadian period (**Figure 4B**) and phase (**Figure 4C**).

[Figure 1 here]

[Figure 2 here]

[Figure 3 here]

[Figure 4 here]

FIGURE LEGENDS:

Figure 1. Sequence of human *PER2* promoter fragment and the circadian reporter vector. (A) Human *PER2* promoter fragment (941 bp) was sequenced, and the sequence was analyzed for the elements of functional circadian promoter. E-box, CACGTT / CATGTG; circadian transcription enhancing site, CCAATG; GC box, CGCCCC / GGGGCGGG; transcription starting site (TSS): CAGCGG. **(B)** Schematic diagram of destabilized luciferase reporter vector, pGL[*hPer2P/Luc2P/Neo*]. The transcription of destabilized luciferase (*dLuc*) is under direct

control of the *hPER2* promoter. A co-expressed neomycin resistance gene (*Neo*) facilitates selection of infected cells by G418.

Figure 2. Synchronization of *in vitro* cellular circadian rhythm by different synchronization agents. After 24 h starvation, MCF10A cells transiently transfected by circadian reporter vector were treated with each synchronization agent for 2 h, followed by recording luminescence signal. Blue, 10 μ M forskolin; red, 1 nM melatonin; green, 0.1 μ M dexamethasone; purple; 50% horse serum (HS); teal, 100% SingleQuot (SQ); yellow, empty vector (negative control). X-axis, time (day); Y-axis, bioluminescence (count/min).

Figure 3. MSC restored cellular circadian rhythms disrupted by NMU and SIRT1 inhibitors in mammary epithelial cells *in vitro*. Bioluminescence assays were performed on MCF10A/*PER2-dLuc* reporter cells after synchronization with 50% HS. X-axis, time (h) (post-NMU treatment time); Y-axis, bioluminescence (count/min). **(A)** Results from transiently transfected cells. **(1)** Cells were treated with 0, 0.25 or 0.5 mM NMU, 20 nM EX527, or 1 μ M cambinol for 1 h following synchronization. Yellow: control; red: 0.25 mM NMU; green: 0.5 mM NMU; blue: 20 nM EX527; yellow green: 1 μ M cambinol. **(2)** Cells were treated with 12.5 μ M MSC alone, or in combination with 20 nM EX527 or 1 μ M cambinol in recording medium following exposure to 0.5 mM NMU. Yellow: Control; red: 0.25 mM NMU; green: 0.5 mM NMU; blue: 0.5 mM NMU + 12.5 μ M MSC; yellow green: 0.5 mM NMU + 12.5 μ M MSC + 20 nM EX527; purple: 0.5 mM NMU + 12.5 μ M MSC + 1 μ M cambinol. **(B)** Results from stably transfected cells. The 3rd – 5th peaks which showed clean and clear differences among groups are presented as a representative result. **(1)** Cells were treated with 0, 0.5, 1.0 or 2.0 mM NMU, 40 nM EX527, or 2 μ M cambinol for 1 h after synchronization. Yellow: Control; red: 0.5 mM NMU; green: 1.0 mM NMU; blue: 2.0 mM NMU; yellow green: 40 nM EX527; purple: 2 μ M cambinol. **(2)** Cells were treated with 12.5 μ M MSC in recording medium following exposure to 1.0 mM NMU. Yellow: Control; red: 1.0 mM NMU; green: 1.0 mM NMU + 12.5 μ M MSC. **(3)** Cells were treated with 12.5 μ M MSC following exposure to 40 nM EX257. Yellow: Control; red: 40 nM EX257; green: 40 nM EX257 + 12.5 μ M MSC. **(4)** Cells were treated with 12.5 μ M MSC following exposure to 2 μ M cambinol. Yellow: Control; red: 2 μ M cambinol; green: 2 μ M cambinol + 25 μ M MSC. This result was previously reported and is licensed under CC BY 2.0²².

Figure 4. NAC dose-dependently restored the cellular circadian rhythm disrupted by NMU. Cells were treated with 1.0 mM NMU or vehicle control for 1 h after synchronization. **(A)** Representative result of bioluminescence (count/min) against time (h). Yellow: Control; red: 1.0 mM NMU; green: 1.0 mM NMU, 5 μ M NAC; blue: 1.0 mM NMU, 10 μ M NAC; yellow green: 1.0 mM NMU, 20 μ M NAC. **(B)** Period (hours). **(C)** Phase (hours).

DISCUSSION:

In mammalian cells, periodicity of the circadian clock is regulated by interconnected transcriptional/translational feedback loops. Heterodimers of Bmal1 and either Clock or Npas2 regulate circadian transcription by binding to E-box elements in the promoters of core CGs, including *Per2* and *Cry*, and numerous CCGs⁴. As they accumulate in the cell, heterodimers of Per:Cry are post-translationally modified and transported to the nucleus to repress Clock:Bmal1

transcriptional activity. This negative feedback loop allows core CGs to regulate their own transcription and set up the rhythmic expression of CGs and CCGs²³. Although most mammalian cells have an intrinsic circadian clock, the clocks in individual cells can be synchronized by both intrinsic conditions (*e.g.*, redox potential) and external environmental stimuli²⁴. Circadian gene expression *in vivo* can be synchronized by melatonin, a hormone produced by the pineal gland in response to signals received from the central pacemaker (SCN). The SCN integrates signals from light impinging on specialized melanopsin-expressing photosensitive retinal ganglion cells in the retina. Melatonin released from the pineal gland enters the circulation and regulates circadian rhythm of SCN and most peripheral cells *in vitro* and *in vivo*^{25,26}. Circadian rhythm can also be regulated by stress hormones (*e.g.*, cortisol and catecholamines)^{27,28} and growth factors^{29,30}. Deregulation of growth factors is known to be associated with circadian disruption of cell growth and differentiation³¹.

The circadian reporter vector we constructed exploits this negative biochemical feedback mechanism. The core circadian negative feedback loop consists of transcriptional activators, BMAL1 and CLOCK, which bind to the circadian E/E'-box binding motifs in *PER2* promoter, and repressors PERs and CRYs, which negatively regulate BMAL1 expression. In the present reporter system, the rhythmic activation of the *PER2* promoter by BMAL1 and CLOCK facilitates circadian expression of destabilized luciferase, allowing for a more accurate circadian periodicity of luminescence signals. The construction of a reporter plasmid includes the BMAL1 binding site, the circadian rhythm enhancing site, GC box, and the transcription start site of the *hPER2* promoter. The vector allows for real-time readout for cellular autonomic circadian rhythm in transfected cells and can be used to identify conditions or specific agents that alter this endogenous circadian pattern of gene expression. However, when cells are cultured *in vitro* or *ex vivo*, their circadian oscillators quickly become desynchronized. It is therefore necessary to resynchronize their rhythms before any circadian assays can be performed *in vitro*. In mammary epithelial cells, we found that 50% HS, melatonin, and 100% SQ were each able to induce efficient synchronization of the circadian rhythm *in vitro*. Dexamethasone and forskolin produced only partial synchronization. Dose-dependent tests would be necessary for the development and selection of new synchronizing agents in future studies. Given the low cost, efficiency and its wide use as the synchronization agent, 50% HS was found to be an effective synchronization agent that produced robust and reproducible cellular circadian rhythm in mammary epithelial cells and neural cells, as previously reported in many other cell types and different experimental settings²⁴.

To validate the *in vitro* model of circadian regulation, we next asked if the response of the circadian rhythm to environmental stressors *in vitro* would recapitulate the effects we observed *in vivo*. Previously, we demonstrated that a single carcinogenic dose of NMU disrupted the circadian expression of major CGs (*e.g.*, *Per2*) and several CCGs in the target mammary gland. Moreover, a chemopreventive regimen of MSC reset the circadian expression of both *Per2* and CCGs genes towards the normal. We further demonstrated that exposure of cells to toxicants and stressors can alter circadian gene expression through their effects on NAD⁺-dependent SIRT1 activity^{7,8,22}. The results obtained using the *in vitro* circadian reporter assay showed that exposure to NMU caused disruption of cellular circadian gene expression, and that more

interestingly, MSC is not only able to reset the cellular circadian rhythm disrupted by NMU, but also reset the circadian rhythm disrupted by the SIRT1 inhibitors. These results indicated that the *in vitro* assay not only reproduces the effects of NMU on circadian gene expression, but also reproduces the effects of MSC on the disrupted circadian rhythm *in vivo* via SIRT1-dependent mechanisms. The *in vitro* circadian reporter system thus has the potential to detect a variety of toxicants and stressors that alter NAD⁺/NADH levels in the cell, including direct inhibitors and modulators of cellular redox cycling as well as genotoxic agents that can deplete NAD⁺ via Poly ADP-ribose dependent DNA repair³². These results suggest that the *in vitro* reporter system provides a useful tool to screen for cell conditions and chemical agents that can disrupt or restore circadian gene regulation *in vivo*.

Although the *in vitro* assay can be set up using cells transiently or stably transfected with the reporter construct, some differences were noted in the response to the treatment of chemicals between transiently and stably transfected cells. The stably transfected cells were more resistant to the treatment of chemicals, particularly NMU and SIRT1 inhibitors, than transiently transfected cells. These differences could reflect subtle differences in regulation of the vector promoter in stable transfectants due to the influences from the sequences surrounding specific integration sites. Therefore, selection of stable transfectants by antibiotic treatment may also select clones that are more resistant to circadian disruption. Thus, individual *in vitro* cell models using transient or stable transfectants must be validated for their ability to recapitulate *in vivo* responses. Different transfection methods also induce varying levels of genotoxic stress and toxicity on cells and result in their different susceptibility to toxic effects of chemicals. Therefore, cytotoxicity test and pilot experiments are required for the selection of transfection and treatment conditions. Despite the difference in their sensitivity, the overall results obtained with our mammary epithelial circadian reporter cells for disruption and restoration of cellular circadian rhythm by chemicals were consistent and comparable between transiently transfected and stably transfected cells, and the results recapitulated the effects we observed *in vivo*.

To determine if the circadian reporter vector could be used in other cell types, human glioblastoma/astrocytoma cells (U-87 MG) were stably transfected with this circadian vector. The preliminary results using the *in vitro* cellular bioluminescence assay showed that after synchronization, these neural-derived tumor cells have a regular and strong cellular circadian rhythm comparable to that observed in human mammary epithelial cells. Cells treated with IC261, a well-known inhibitor of casein kinase 1 δ (CK1 δ) and CK1 ϵ , showed a prolonged circadian period, but lower amplitude as reported by others (data not shown)³³. These results indicate that the circadian luciferase reporter vector and *in vitro* cellular bioluminescence assay are applicable in other organ specific cells, including neural cells.

The cellular reporter system developed here could therefore be used broadly as an *in vitro* assay for determination of circadian gene expression in different cell types in general. The experimental procedure is simple, fast, and safe. However, this cellular reporter system cannot be readily adapted in cells that are difficult to transfect, non-dividing cells (*e.g.*, neuronal cells), since they have notoriously low transfection efficiencies. Virus-based transfection methods

(e.g., lentivirus transfection) may offer a higher efficiency solution for these cells³⁴. However, the time and difficulty associated with lentiviral production makes this method difficult and time consuming. Moreover, a proper safety-level lab is necessary for production and use of the virus. In addition, high resolution single cell luminescence detectors could be used for the determination of persistent, independently-phased rhythms of circadian gene expression in non-dividing cells³⁵.

Studies of mammalian circadian rhythm *in vivo* are not only labor intensive, and costly, but they also require the use of large numbers of animals. The availability of *in vitro* systems could significantly reduce the number of animals required to test associations between disruption of circadian gene expression and the development of chronic diseases, including carcinogenesis and metabolic syndrome. Quantitative data on circadian parameters, including period, amplitude, and phase, can inform dose- and/or time-dependent effects of chemicals on cellular circadian rhythm. For example, we observed that antioxidant NAC can dose-dependently restore the period and phase of cellular circadian rhythm disrupted by NMU. The *in vitro* model could also be used to screen and classify environmental circadian disruptors and to investigate the impact of disrupted circadian rhythm on the impairment of cellular function, providing mechanistic insights for the development of intervention strategies for cohorts at increased risk to breast cancer, metabolic syndromes, and neurophysiological disorders, because of abnormal work schedules.

ACKNOWLEDGEMENT:

This work was supported by the 2012 Society of Toxicology (SOT)-Colgate Palmolive Grant for Alternative Research (M. Fang) and the international collaboration research fund from Animal and Plant Quarantine Agency, Republic of Korea (M. Fang), and the NIEHS grant P30ES005022 (H. Zarbl). We would like to thank Dr. Zheng Chen (McGovern Medical School at The University of Texas Health Science Center at Houston) for his helpful discussion, Mr. Shao-An Juan for his experimental assistance, and Ms. Kimi Nakata for her proof reading.

DISCLOSURES:

The authors have nothing to disclose.

REFERENCES:

- 1 Akerstedt, T. *et al.* Night work and breast cancer in women: a Swedish cohort study. *BMJ Open*. **5** (4), e008127, doi:10.1136/bmjopen-2015-008127, (2015).
- 2 Parent, M. E., El-Zein, M., Rousseau, M. C., Pintos, J. & Siemiatycki, J. Night work and the risk of cancer among men. *Am J Epidemiol*. **176** (9), 751-759, doi:10.1093/aje/kws318, (2012).
- 3 Knutsson, A. *et al.* Breast cancer among shift workers: results of the WOLF longitudinal cohort study. *Scand J Work Environ Health*. **39** (2), 170-177, doi:10.5271/sjweh.3323, (2013).
- 4 Fu, L. & Lee, C. C. The circadian clock: pacemaker and tumour suppressor. *Nat Rev Cancer*. **3** (5), 350-361, doi:10.1038/nrc1072nrc1072, (2003).
- 5 Fu, L. & Kettner, N. M. The circadian clock in cancer development and therapy. *Prog Mol Biol Transl Sci*. **119** 221-282, doi:10.1016/B978-0-12-396971-2.00009-9, (2013).

- 6 IARC. Painting, Firefighting, and Shiftwork. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans* **98** 563-764 (2010).
- 7 Zhang, X. & Zarbl, H. Chemopreventive doses of methylselenocysteine alter circadian rhythm in rat mammary tissue. *Cancer Prev Res (Phila Pa)*. **1** (2), 119-127 (2008). doi:10.1158/1940-6207.CAPR-08-0036
- 8 Fang, M. Z., Zhang, X. & Zarbl, H. Methylselenocysteine resets the rhythmic expression of circadian and growth-regulatory genes disrupted by nitrosomethylurea in vivo. *Cancer Prev Res (Phila)*. **3** (5), 640-652, doi:1940-6207.CAPR-09-0170 10.1158/1940-6207.CAPR-09-0170, (2010).
- 9 Burbulla, L. F. & Kruger, R. Converging environmental and genetic pathways in the pathogenesis of Parkinson's disease. *J Neurol Sci*. **306** (1-2), 1-8, doi:S0022-510X(11)00186-9 10.1016/j.jns.2011.04.005, (2011).
- 10 Aitlhadj, L., Avila, D. S., Benedetto, A., Aschner, M. & Sturzenbaum, S. R. Environmental exposure, obesity, and Parkinson's disease: lessons from fat and old worms. *Environ Health Perspect*. **119** (1), 20-28, doi:10.1289/ehp.1002522, (2011).
- 11 Nagoshi, E., Brown, S. A., Dibner, C., Kornmann, B. & Schibler, U. Circadian gene expression in cultured cells. *Methods Enzymol*. **393** 543-557, doi:S0076687905930280 10.1016/S0076-6879(05)93028-0, (2005).
- 12 Ramanathan, C. *et al*. Cell type-specific functions of period genes revealed by novel adipocyte and hepatocyte circadian clock models. *PLoS Genet*. **10** (4), e1004244, doi:10.1371/journal.pgen.1004244, (2014).
- 13 Sporl, F. *et al*. A circadian clock in HaCaT keratinocytes. *J Invest Dermatol*. **131** (2), 338-348, doi:10.1038/jid.2010.315, (2011).
- 14 Zhang, E. E. *et al*. A genome-wide RNAi screen for modifiers of the circadian clock in human cells. *Cell*. **139** (1), 199-210, doi:10.1016/j.cell.2009.08.031, (2009).
- 15 Yoo, S. H. *et al*. PERIOD2::LUCIFERASE real-time reporting of circadian dynamics reveals persistent circadian oscillations in mouse peripheral tissues. *Proc Natl Acad Sci U S A*. **101** (15), 5339-5346, doi:10.1073/pnas.03087091010308709101, (2004).
- 16 Leclerc, G. M., Boockfor, F. R., Faught, W. J. & Frawley, L. S. Development of a destabilized firefly luciferase enzyme for measurement of gene expression. *Biotechniques*. **29** (3), 590-591, 594-596, 598 passim (2000).
- 17 Genomics, S. *Technical Note: SwitchGear methods for gene model construction and transcription start site prediction*. (2009).
- 18 Scientific, F. Safety Data Sheet: Ethidium bromide, 1% Solution/Molecular Biology. (2010).
- 19 Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. *Current Protocols in Molecular Biology* (New York: Greene Publishing Associates and Wiley-Interscience). (1994).
- 20 Yoo, S. H. *et al*. A noncanonical E-box enhancer drives mouse Period2 circadian oscillations in vivo. *Proc Natl Acad Sci U S A*. **102** (7), 2608-2613, doi:10.1073/pnas.0409763102, (2005).
- 21 Chen, Z. *et al*. Identification of diverse modulators of central and peripheral circadian clocks by high-throughput chemical screening. *Proc Natl Acad Sci U S A*. **109** (1), 101-106, doi:10.1073/pnas.1118034108, (2012).

- 22 Fang, M., Guo, W. R., Park, Y., Kang, H. G. & Zarbl, H. Enhancement of NAD⁺-dependent SIRT1 deacetylase activity by methylselenocysteine resets the circadian clock in carcinogen-treated mammary epithelial cells. *Oncotarget*. doi:10.18632/oncotarget.6002, (2015).
- 23 Chen-Goodspeed, M. & Lee, C. C. Tumor suppression and circadian function. *J Biol Rhythms*. **22** (4), 291-298 (2007).
- 24 Balsalobre, A. Clock genes in mammalian peripheral tissues. *Cell Tissue Res*. **309** (1), 193-199 (2002).
- 25 Jung-Hynes, B., Huang, W., Reiter, R. J. & Ahmad, N. Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. *J Pineal Res*. **49** (1), 60-68.
- 26 von Gall, C. *et al.* Melatonin plays a crucial role in the regulation of rhythmic clock gene expression in the mouse pars tuberalis. *Ann N Y Acad Sci*. **1040** 508-511 (2005).
- 27 Vujovic, N., Davidson, A. J. & Menaker, M. Sympathetic input modulates, but does not determine, phase of peripheral circadian oscillators. *Am J Physiol Regul Integr Comp Physiol*. **295** (1), R355-360, doi:00498.2007 10.1152/ajpregu.00498.2007, (2008).
- 28 Schofl, C., Becker, C., Prank, K., von zur Muhlen, A. & Brabant, G. Twenty-four-hour rhythms of plasma catecholamines and their relation to cardiovascular parameters in healthy young men. *Eur J Endocrinol*. **137** (6), 675-683 (1997).
- 29 Yu, H. *et al.* Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. *Clin Chem*. **57** (5), 691-700, doi:10.1373/clinchem.2010.155184, (2011).
- 30 Nakagawa, H. *et al.* Modulation of circadian rhythm of DNA synthesis in tumor cells by inhibiting platelet-derived growth factor signaling. *J Pharmacol Sci*. **107** (4), 401-407 (2008).
- 31 Yang, X., Guo, M. & Wan, Y. J. Deregulation of growth factor, circadian clock, and cell cycle signaling in regenerating hepatocyte RXR α -deficient mouse livers. *Am J Pathol*. **176** (2), 733-743, doi:10.2353/ajpath.2010.090524, (2010).
- 32 Virag, L. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies. *Curr Vasc Pharmacol*. **3** (3), 209-214 (2005).
- 33 Kon, N., Sugiyama, Y., Yoshitane, H., Kameshita, I. & Fukada, Y. Cell-based inhibitor screening identifies multiple protein kinases important for circadian clock oscillations. *Commun Integr Biol*. **8** (4), e982405, doi:10.4161/19420889.2014.982405, (2015).
- 34 Ramanathan, C., Khan, S. K., Kathale, N. D., Xu, H. & Liu, A. C. Monitoring Cell-autonomous Circadian Clock Rhythms of Gene Expression Using Luciferase Bioluminescence Reporters. (67), e4234, doi:doi:10.3791/4234, (2012).
- 35 Welsh, D. K., Yoo, S. H., Liu, A. C., Takahashi, J. S. & Kay, S. A. Bioluminescence imaging of individual fibroblasts reveals persistent, independently phased circadian rhythms of clock gene expression. *Curr Biol*. **14** (24), 2289-2295, doi:S0960982204009157 10.1016/j.cub.2004.11.057, (2004).

A

CATGTT E-box -166 ~ -160 bp
CAATG E-box -156 ~ -150 bp
CAATG Circadian Transcription Enhancing Site -64 ~ -58 bp; -127 ~ -121 bp
TGCTG / **TTGCTG** GC box -99 ~ -93 bp
CACGTT E'-box -25 ~ -19 bp
CATCGG Transcription Starting Site (TSS)

B




Fig. 2




Fig. 3





Figure 4



Material/ Equipment

Name	Company	Catalog Number
pLS[hPER2P/rLuc/Puro] vector	SwitchGear Genomics	S700000
pGL4.18[Luc2P/Neo] vector	Promega	9PIE673
T4 DNA ligase	Invitrogen	15224041
TOPO TA cloning kit	Invitrogen	K4500-02
Sac I	New England BioLabs	R0156S
Hind III-HF	New England BioLabs	R3104S
CutSmart buffer	New England BioLabs	B7204S
DNA gel extraction kit	Qiagen	28704
PCR Purification Kit	Qiagen	28104
LB Miller's modification	TEKNOVA	L8600
LB Agar Plate	TEKNOVA	L1902
QIAprep spin miniprep Kit	Qiagen	27104
EndoFree plasmid maxi prep Kit	Qiagen	12362
FuGene HD	Promega	E2311
Opti-MEM reduced serum medium	Invitrogen	31985-062
MCF10A cell line	American Type Culture Collection	CRL-10317
MEGM BulletKit	Lonza	CC-3150
MEBM	Lonza	CC-3151
MEGM SingleQuot Kit	Lonza	CC-4136
ReagentPack	Lonza	CC-5034
D-PBS (10X)	Sigma	D1408
UltraPure Distilled Water	Invitrogen	10977
Tissue culture dish (35 mm)	BD/Falcon	353001
Silicon grease	Fisher	NC9044707
Round cover glass	Harvard Bioscience	64-1500 (CS-40R)
Cholera toxin	Sigma	C8052
G418 sulfate (Genitacin)	Invitrogen	10131035

Ampicillin	Sigma	A9393
Forskolin	Sigma	F6886
Melatonin	Sigma	M5250
Dexamethasone	Sigma	D4902
Horse serum	Sigma	H1138
d-Luciferin, sodium salt	Invitrogen	L2912
IC261	Sigma	10658
Methylnitrosourea (NMU)	Sigma	N1517
Methylselenocysteine (MSC)	Sigma	M6680
EX527	Sigma	E7034
Cambinol	Sigma	C0494
NanoDrop Spectrophotometer	Thermo Scientific	NanoDrop 8000
GeneAmp PCR System 9700	Applied Biosystems	N805-0200
CO2 Incubator	NAPCO	Series 8000 DH
Desktop centrifuge with refrezerator	Eppendorf	5430R
Centrifuge with swing bucket	Eppendorf	5810 R
Inverted microscope	Nikon	80124
Tissue culture hood	Labconco	Class II A2
LumiCycle 32	Actimetrics	Not Available

Comments/Description

customized vector
destabilized luciferase expression vector
For subcloning
with One Shot TOP10 Chemically Competent *E. coli*
Restriction enzyme
Restriction enzyme
Restriction enzyme buffer
Purify DNA fragments from agarose gel
DNA clean up
For transformed *E. Coli* culture
For white/blue selection
For extraction of plasmide DNA
For extraction of plasmide DNA
Transfection reagent
For transfection

Mammary Epithelial Cells
Mammary Epithelial Growth Medium
Mammary Epithelial Basal Medium
Suppliments & Growth Factors
Reagent for subculture
Wash cells in culture dishes
Dilute 10X D-PBS
cell culture dish suitable to LumiCycle
For sealing dish with recording medium
For sealing dish with recording medium
Supplement for growth medium
Antibiotic for selection of stabliy transfected cells

For colony selection
Synchronization agent
Synchronization agent
Synchronization agent
Synchronization agent
Luciferase substrate
Positive control for circadian disruptor
Mammary specific carcinogen
Organic selenium (chemopreventive agent)
SIRT1 specific inhibitor
SIRT1 & SIRT2 inhibitor
Quantify nucleotide
For molecular biology experiment
For cell culture at 5% CO₂ at 37 °C
For molecular biology experiment
For cell culture
Phase contrast optional
BSL-2 certified
Luminoscence detector



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

In Vitro Bioluminescence Assay to Characterize Circadian Rhythm in Mammary Epithelial Cells

Author(s):

Mingzhu Fang, Hwan-Goo Kang, Youngil Park, Brian Estrella and Helmut Zerbe

Item 1 (check one box): The Author elects to have the Materials be made available (as described at

<http://www.jove.com/author>) via: ☒ Standard Access ☐ Open Access

Item 2 (check one box):

- ☒ The Author is NOT a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: "Agreement" means this Article and Video License Agreement; "Article" means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; "Author" means the author who is a signatory to this Agreement; "Collective Work" means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; "CRC License" means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; "Derivative Work" means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; "Institution" means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; "JoVE" means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; "Materials" means the Article and / or the Video; "Parties" means the Author and JoVE; "Video" means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to Sections 4 and 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in Item 1 above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in Section 3 above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This Section 5 applies if the "Standard Access" box has been checked in Item 1 above or if no box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to Section 7 below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This Section 6 applies only if the "Open Access" box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to Section 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in Item 2 above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have

ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. Indemnification. The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's

expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. Fees. To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. Transfer, Governing Law. This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

CORRESPONDING AUTHOR:

Name: Mingzhu Fang
Department: Environmental and Occupational Health
Institution: School of Public Health
Article Title: In Vitro Bioluminescence Assay to Characterize Circadian Rhythm in Mammary Epithelial Cells
Signature: Mingzhu Fang Date: 12/9/16

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email submissions@jove.com or call +1.617.945.9051

Response to ER comments on 55832_R1_041817

1. We moved the Note for luciferase vectors to Introduction.
2. Highlighted 1.1 to show the construction map in video.
3. Added DNA quantification method in many lines of many sections as recommended.
4. Added medium name (MEGM) and culture conditions (in cell culture incubator at 37 °C, 95% humidity and 5% CO₂) in many lines of many sections as recommended.
5. Revised sentence in line 347.
6. Revised sentences in lines 359-360.
7. Added more detained information in lines 363-365.
8. Added unit (counts/min) of bioluminescence in Fig. 2, Fig. 3, and Fig. 4, and their legends.
9. Deleted “e” and revised as “SingleQuot”.
10. Added literature # (22) at the end of line 525.
11. Took off the SE in the Fig. 4 and revised its legend as concerned.
12. Revised Acknowledgement by adding “M. Fang” in line 668 and adding Dr. Zheng Chen in lines 648-649.